Furiex Pharmaceuticals, Inc. ( FURX ) was a big mover last session, as the company saw its shares rise by nearly 130% on the day. The move came on solid volume too with far more shares changing hands than in a normal session after the company reported positive results from two late-stage studies of eluxadoline for patients suffering from diarrhea-predominant irritable bowel syndrome. The stock picked up sharply from the near-flat trend of $41.72 to $47.40 in the past one-month time frame.
This biopharmaceutical stock has seen no estimate revision over the past 7 days, while the Zacks Consensus Estimate remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Furiex currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same industry include DepoMed Inc. ( DEPO ), Endocyte, Inc. ( ECYT ) and Salix Pharmaceuticals Ltd. ( SLXP ). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
DEPOMED INC (DEPO): Get Free Report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
FURIEX PHARMACT (FURX): Free Stock Analysis Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research